S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Forecast, Price & News

$10.95
-0.26 (-2.32%)
(As of 09/29/2023 ET)
Compare
Today's Range
$10.81
$11.27
50-Day Range
$10.95
$14.60
52-Week Range
$10.81
$23.00
Volume
275,037 shs
Average Volume
213,340 shs
Market Capitalization
$391.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.33

iTeos Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
231.8% Upside
$36.33 Price Target
Short Interest
Bearish
5.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.09mentions of iTeos Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$5.69 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.19) to ($5.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

643rd out of 972 stocks

Biological Products, Except Diagnostic Industry

97th out of 155 stocks


ITOS stock logo

About iTeos Therapeutics (NASDAQ:ITOS) Stock

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Price History

ITOS Stock News Headlines

iTeos to Participate in Upcoming Investor Conferences
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Why ITeos Therapeutics (ITOS) Stock Is Moving Higher
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
H.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)
iTeos Therapeutics: Trading Under Cash Value
iTeos Therapeutics (ITOS) Gets a Buy from H.C. Wainwright
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITOS Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.33
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+231.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$96.65 million
Pretax Margin
-31.00%

Debt

Sales & Book Value

Annual Sales
$267.63 million
Cash Flow
$2.69 per share
Book Value
$18.65 per share

Miscellaneous

Free Float
32,132,000
Market Cap
$391.79 million
Optionable
Not Optionable
Beta
1.20
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Michel Detheux Ph.D. (Age 57)
    Pres, CEO & Director
    Comp: $922.38k
  • Mr. Matthew A. Call M.B.A. (Age 50)
    Chief Operating Officer
    Comp: $638.55k
  • Mr. Matthew GallMr. Matthew Gall (Age 46)
    Chief Financial Officer
  • Dr. Yvonne McGrath Ph.D. (Age 49)
    Chief Scientific Officer
  • Mr. Ryan Baker
    Head of Investor Relations
  • Ms. Adi Osovsky
    VP & Head of Legal
  • Mr. Phillipe Brantegem
    Vice-Pres of HR













ITOS Stock - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings
or view top-rated stocks.

What is iTeos Therapeutics' stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year price targets for iTeos Therapeutics' shares. Their ITOS share price forecasts range from $32.00 to $44.00. On average, they predict the company's share price to reach $36.33 in the next twelve months. This suggests a possible upside of 231.8% from the stock's current price.
View analysts price targets for ITOS
or view top-rated stocks among Wall Street analysts.

How have ITOS shares performed in 2023?

iTeos Therapeutics' stock was trading at $19.53 on January 1st, 2023. Since then, ITOS shares have decreased by 43.9% and is now trading at $10.95.
View the best growth stocks for 2023 here
.

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ITOS earnings forecast
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) released its earnings results on Tuesday, August, 8th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.07. iTeos Therapeutics had a negative trailing twelve-month return on equity of 4.42% and a net margin of 9.02%.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

(ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is iTeos Therapeutics' stock symbol?

iTeos Therapeutics trades on the NASDAQ under the ticker symbol "ITOS."

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iTeos Therapeutics' stock price today?

One share of ITOS stock can currently be purchased for approximately $10.95.

How much money does iTeos Therapeutics make?

iTeos Therapeutics (NASDAQ:ITOS) has a market capitalization of $391.79 million and generates $267.63 million in revenue each year. The company earns $96.65 million in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does iTeos Therapeutics have?

The company employs 125 workers across the globe.

How can I contact iTeos Therapeutics?

The official website for the company is www.iteostherapeutics.com. The company can be reached via phone at 339-217-0161 or via email at ir@iteostherapeutics.com.

This page (NASDAQ:ITOS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -